SCHEMBL253350

SCHEMBL253350

C=CCNS(=O)(=O)c1ccccc1S(N)(=O)=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.48
KDM4E B2RXH2 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2D6 P10635 1/20 0.48
CASP1 P29466 1/20 0.48
CASP7 P55210 1/20 0.48
CA1 P00915 10/20 0.45
CA2 P00918 10/20 0.45
CA9 Q16790 7/20 0.45
CA12 O43570 4/20 0.45
CA14 Q9ULX7 2/20 0.44
CA6 P23280 3/20 0.42
CA5A P35218 2/20 0.42
CA7 P43166 2/20 0.42
CA5B Q9Y2D0 2/20 0.42
CA4 P22748 2/20 0.41
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
NPSR1 Q6W5P4 1/20 0.38
PTGES O14684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11667123 0.83 KDM4E (0.54) CYP2C9KDM4ECYP1A2CYP2D6CASP1
SCHEMBL16831449 0.83 RECQL (0.53) CYP2C9KDM4ECYP1A2CYP2D6CASP1
SCHEMBL6443974 0.83 CA9 (0.47) CYP2C9KDM4ECYP1A2CYP2D6CASP1
SCHEMBL10616445 0.83 KDM4E (0.45) CYP2C9KDM4ECYP1A2CYP2D6CASP1
SCHEMBL4070788 0.79 TSHR (0.49) CYP2C9KDM4ECYP1A2CYP2D6CASP1
SCHEMBL4564656 0.78 KDM4E (0.44) CYP2C9KDM4ECYP1A2CYP2D6CASP1
SCHEMBL29700285 0.78 CASP1 (0.50) CYP2C9KDM4ECYP1A2CYP2D6CASP1
SCHEMBL7906849 0.77 KDM4E (0.59) CYP2C9KDM4ECYP1A2CYP2D6CASP1
SCHEMBL4790234 0.77 CA12 (0.52) CYP2C9KDM4ECYP1A2CYP2D6CASP1
SCHEMBL4761072 0.77 KDM4E (0.43) CYP2C9KDM4ECYP1A2CYP2D6CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088752-B2 Methods for metabolic modulation VDF FUTURECEUTICALS, INC. (US) 2012-01-03 US disclosed
US-20090208620-A1 Alimentary Compositions and Methods For Metabolic Modulation VDF FUTURECEUTICALS, INC. (US) 2009-08-20 US disclosed
US-20090203638-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION VDF FUTURECEUTICALS, INC. (US) 2009-08-13 US disclosed
US-20070184067-A1 Alimentary compositions and methods for metabolic modulation VDF FUTURECEUTICALS 2007-08-09 US disclosed
US-20070161582-A1 Pharmaceutical compositions and methods for metabolic modulation VDF FUTURECEUTICALS 2007-07-12 US disclosed
WO-2005020892-A2 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION MITOCHROMA RESEARCH, INC. (US) 2005-03-10 WO disclosed
WO-2005016268-A2 ALIMENTARY COMPOSITIONS AND METHODS FOR METABOLIC MODULATION MITOCHROMA RESEARCH, INC. (US) 2005-02-24 WO disclosed
US-4064239-A LIVER FLUKES MERCK & CO., INC. (US) 1977-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161582-A1 Pharmaceutical compositions and methods for metabolic modulation GPR119, PRKAG2, PRKAG1 CYP2C9 3452/4885KDM4E 4093/4885CYP1A2 2366/4885
US-20090203638-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION GPR119, PRKAG2, GCKR CYP2C9 3363/4885KDM4E 4031/4885CYP1A2 2313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.